ライフサイエンスコーパス: poly ADP-ribose polymerase

1 elastatin-like 2 (TRPM2), via stimulation of poly-ADP-ribose polymerase.

2 e consisting of caspase-3 and -7 and cleaved poly(ADP)-ribose polymerase.

3 ch, in turn, activates the DNA repair enzyme poly(ADP)-ribose polymerase.

4 tential pharmaceutical target tankyrase 1, a poly(ADP-ribose) polymerase.

5 hondria, caspase 3 activity, and cleavage of poly(ADP-ribose) polymerase.

6 caspase-3 and cleaved the caspase substrate poly(ADP-ribose) polymerase.

7 f apoptotic mediators, such as caspase-3 and poly(ADP-ribose) polymerase.

8 ncreased the expression of apoptotic cleaved poly(ADP-ribose) polymerase.

9 zed human cells to olaparib, an inhibitor of poly(ADP-ribose) polymerase.

10 release, caspase 3 activity, and cleavage of poly (ADP-ribose) polymerase.

11 HR, but confers sensitivity to inhibition of poly(ADP-ribose) polymerases.

12 ious enzyme families, including sirtuins and poly(ADP-ribose) polymerases.

13 ide together with velaparib, an inhibitor of poly (ADP ribose) polymerase 1, is increased by up to 10

14 005) concomitant with an increase in cleaved poly (ADP-ribose) polymerase 1 (P < 0.05), indicative of

15 Poly (ADP-ribose) polymerase 1 (PARP-1) is a constitutiv

16 Inhibition of beta-catenin, poly (ADP-ribose) polymerase 1 (PARP1), or enhancer of z

17 langiectasia mutated (ATM), but dependent on poly (ADP-ribose) polymerase 1 (PARP1), which ADP ribosy

18 lementing protein 1, DNA polymerase beta, or poly (ADP-ribose) polymerase 1 activity, all of which fa

19 oughput screens identified multiple clinical poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitor

20 Poly [ADP ribose] polymerase 1 (PARP-1) is proinflammato

21 Poly [ADP-ribose] polymerase 1 (PARP-1) is a highly abun

22 -1) liposomes were used to deliver a PARP-1 (poly [ADP-ribose] polymerase 1) inhibitor: AZ7379.

23 and (2) the alternative pathway initiated by poly ADP-ribose polymerase 1 (PARP1).

24 logous end-joining DNA repair process and in poly ADP-ribose polymerase 1 activation.

25 eference as caspase-3, is better at cleaving poly(ADP ribose) polymerase 1 (PARP) and Hsp90 cochapero

26 nents of the topoisomerase IIbeta (TOP2beta)/poly(ADP ribose) polymerase 1 (PARP1) complex are necess

27 ingly, mtp53 depletion profoundly influenced poly(ADP ribose) polymerase 1 (PARP1) localization, with

28 ion, Rev1-deficiency is associated with high poly(ADP) ribose polymerase 1 (PARP1) activity, low endo

29 ing, whereas DNA repair pathways mediated by poly(ADP)ribose polymerase 1 (PARP1) serve as backups.

30 Poly(ADP-ribose) polymerase 1 (PARP-1) is a cellular enz

31 ins DNA-dependent protein kinase (DNA-PK) or poly(ADP-ribose) polymerase 1 (PARP-1) prevented the DNA

32 B and SP1 bind to a composite element in the poly(ADP-ribose) polymerase 1 (PARP-1) promoter in a mut

33 Here, we identify poly(ADP-ribose) polymerase 1 (PARP1) as a novel DDB2-as

34 Here, we identify poly(ADP-ribose) polymerase 1 (PARP1) as a previously un

35 investigated the regulation of mitochondrial poly(ADP-ribose) polymerase 1 (PARP1) by the cyclic aden

36 Poly(ADP-ribose) polymerase 1 (Parp1) catalyzes poly(ADP

37 ation of caspase 3 and caspase 9, along with poly(ADP-ribose) polymerase 1 (PARP1) cleavage, which is

38 The nuclear enzyme poly(ADP-ribose) polymerase 1 (PARP1) has been shown to

39 Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors were re

40 Poly(ADP-ribose) polymerase 1 (PARP1) interacts genetica

41 n Xenopus egg extract assays, we showed that poly(ADP-ribose) polymerase 1 (PARP1) is modified by SUM

42 poly(ADP-ribosyl)ation mediated primarily by poly(ADP-ribose) polymerase 1 (PARP1) is responsible for

43 Here we show that the enzyme poly(ADP-ribose) polymerase 1 (PARP1) modifies PAP and r

44 ity in identifying ADP-ribosylation sites on Poly(ADP-ribose) Polymerase 1 (PARP1) with mass spectrom

45 h increased expression of DNA ligase 3alpha, poly(ADP-ribose) polymerase 1 (PARP1), and X-ray repair

46 -ribose (PAR) chains, primarily catalyzed by poly(ADP-ribose) polymerase 1 (PARP1), is crucial for ce

47 apurinic/apyrimidinic endonuclease 1 (APE1), poly(ADP-ribose) polymerase 1 (PARP1), X-ray repair cros

48 D(+)-dependent auto-poly-ADP-ribosylation of poly(ADP-ribose) polymerase 1 (PARP1).

49 poly(ADP-ribose) (PAR) is mediated mainly by poly(ADP-ribose) polymerase 1 (PARP1).

50 Poly(ADP-ribose) polymerase 1 (PARP1, also known as ARTD

51 , we found that recruitment was dependent on poly(ADP-ribose) polymerase 1 activity as well as Kdm4b

52 oskeleton while promoting the degradation of poly(ADP-ribose) polymerase 1, an inhibitor of osteoclas

53 hat the SNAT2 ER-alpha-ERE complex contained poly(ADP-ribose) polymerase 1, Lupus Ku autoantigen prot

54 t assay, quantification of 8-oxoguanine, and poly(ADP-ribose) polymerase 1.

55 ers, including cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase 1.

56 Poly(ADP-ribose)polymerase 1 (PARP-1) is a key eukaryoti

57 Here, we demonstrate that the nuclear enzyme Poly(ADP-ribose)Polymerase 1 (PARP1) is a promising targ

58 e, lack of hepatocyte HMGB1 led to excessive poly(ADP-ribose)polymerase 1 activation, exhausting nico

59 teady state levels of two ALT NHEJ proteins, poly-(ADP-ribose) polymerase 1 (PARP1) and DNA ligase II

60 iated by the nuclear ADP-ribosylating enzyme poly-(ADP-ribose) polymerase 1 (PARP1) and the deribosyl

61 tion and activation of the DNA damage sensor poly-ADP ribose polymerase 1 (PARP1).

62 yl)ation (PARylation) is mainly catalysed by poly-ADP-ribose polymerase 1 (PARP1), whose role in gene

63 PET imaging strategy for DLBCL that targets poly[ADP ribose] polymerase 1 (PARP1), the expression of

64 (ATM), phosphorylated H2AX (gammaH2AX), and poly[ADP-ribose] polymerase 1 (PARP-1).

65 thodologies for studying robust responses of poly (ADP-ribose) polymerase-1 (PARP-1) to DNA damage wi

66 Poly (ADP-ribose) polymerase-1 (PARP1) is a highly conse

67 ent of targeted agents such as inhibitors of poly (ADP-ribose) polymerase-1 and mTOR and immunomodula

68 Purpose To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is

69 of UVA laser induced damage in cells lacking poly (ADP-ribose) polymerase-1.

70 ADAMTS-4 directly cleaved and degraded poly ADP ribose polymerase-1 (a key molecule in DNA repa

71 1/cell-cycle, apoptotic genes, caspase-3 and poly ADP ribose polymerase-1 (PARP-1) cleavage) and was

72 large Ca(2+) and Na(+) influx, activation of poly(ADP ribose) polymerase-1 (PARP-1), and delayed Ca(2

73 ecting parthanatos, monitored by cleavage of poly(ADP ribose)polymerase-1 (PARP-1), or necroptosis, a

74 Neuronal poly(ADP-ribose) polymerase-1 (PARP-1) activation in dia

75 ze nuclear LXRalpha complexes and identified poly(ADP-ribose) polymerase-1 (PARP-1) as an LXR-associa

76 Poly(ADP-ribose) polymerase-1 (PARP-1) creates the postt

77 This work focuses on the regulation of poly(ADP-ribose) polymerase-1 (PARP-1) expression by MKP

78 The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-establ

79 Interest in nuclear imaging of poly(ADP-ribose) polymerase-1 (PARP-1) has grown in rece

80 Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant nu

81 We show here that Poly(ADP-ribose) polymerase-1 (PARP-1) regulates TGF-bet

82 Massive poly(ADP-ribose) formation by poly(ADP-ribose) polymerase-1 (PARP-1) triggers NAD depl

83 PAH-PASMCs have increased the activation of poly(ADP-ribose) polymerase-1 (PARP-1), a critical enzym

84 poly(ADP-ribosyl)ation (i.e., PARylation) of poly(ADP-ribose) polymerase-1 (PARP-1), a multifunctiona

85 Poly(ADP-ribose) polymerase-1 (PARP-1), a ubiquitous and

86 yrin repeat-containing protein that mediates poly(ADP-ribose) polymerase-1 (PARP-1)-dependent transcr

87 IL-1, controls gene expression by activating poly(ADP-ribose) polymerase-1 (PARP-1).

88 is catalytic activation of a nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1).

89 he DNA-dependent protein kinase (DNA-PK) and Poly(ADP-ribose) polymerase-1 (PARP1) are critical enzym

90 physiological activity of the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP1) causes neuron deat

91 ss of dopaminergic neurons via activation of poly(ADP-ribose) polymerase-1 (PARP1).

92 This was linked to suppressed poly(ADP-ribose) polymerase-1 activity and was reversibl

93 is able to recruit the transcription factors poly(ADP-ribose) polymerase-1 and splicing factor prolin

94 cells was linked to defective degradation of poly(ADP-ribose) polymerase-1.

95 Herein, we demonstrate that poly(ADP-ribose)polymerase-1 (PARP-1) is a genome-wide e

96 repair; we found that salidroside activated poly(ADP-ribose)polymerase-1 (PARP-1), a component of th

97 e synthesized and evaluated as inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).

98 c chromatin condensation as well as distinct poly(ADP-ribose)polymerase-1 cleavage.

99 d for sensitizing BRCA1-deficient tumours to poly-ADP-ribose polymerase-1 (PARP) inhibitors.

100 (miRs), matrix metalloproteinases (MMPs) and poly-ADP-ribose-polymerase-1 (PARP-1) in diabetic kidney

101 Poly(ADP-ribose) polymerase-13 (PARP13/ZAP/ZC3HAV1) is a

102 poly-(ADP-ribose) polymerase 14 (PARP14), an intracellul

103 Interestingly, miR-149 inhibits poly(ADP-ribose) polymerase-2 (PARP-2) and so increased

104 Poly(ADP-ribose) polymerase-2 (PARP-2) is one of three h

105 Here we show that Poly(ADP-ribose) polymerase-2 (Parp-2) plays an essentia

106 and RAD50 as suppressors and 53BP1, DDB1 and poly(ADP)ribose polymerase 3 (PARP3) as promoters of chr

107 Increasing evidence define Poly(ADP-ribose) polymerase 3 (PARP3, also known as ARTD

108 caspase-9 and caspase-3 and the cleavage of poly (ADP-ribose) polymerase; (5) upregulating pancreati

109 However, poly(ADP-ribose) polymerase, a protein involved in DNA r

110 increase in caspase-3, cytochrome c release, poly(ADP-ribose) polymerase activation, down-regulation

111 reatly reduced or ablated by an inhibitor of poly (ADP-ribose) polymerase activity.

112 including HMGN1 and RFC1; and regulation of poly(ADP-ribose) polymerase activity.

113 lies of enzymes consume NAD(+) as substrate: poly(ADP-ribose) polymerases, ADP-ribosyl cyclases (CD38

114 ROS and poly(ADP-ribose) polymerase also reduce sirtuin, PGC-1al

115 these conditions correlates with cleavage of poly(ADP-ribose) polymerase, an indicator of apoptosis.

116 termined by Western blot analysis of cleaved poly (ADP-ribose) polymerase and caspase 3.

117 e-9 and -3 that, in turn, led to cleavage of poly(ADP ribose) polymerase and Mcl-1.

118 is (p53, Fas, and MST1), DNA damage control (poly(ADP)-ribose polymerase and ataxia telangiectasia mu

119 1-XPF endonuclease in cooperation with PARP1 poly(ADP-ribose) polymerase and RPA The novel gap format

120 P-ribose) (pADPr) can be rapidly produced by poly(ADP-ribose) polymerases and degraded by poly(ADP-ri

121 Poly-ADP ribose polymerase and aurora kinase inhibitors

122 creased levels of apoptotic markers, cleaved poly (ADP-ribose) polymerase, and caspase-3 and -8 (P <

123 tivation of caspase-8, caspase-9, caspase-3, poly (ADP-ribose) polymerase, and downregulation of Mcl-

124 is, and activation of caspase-3, -7, -8, -9, poly (ADP-ribose) polymerase, and lamin A/C.

125 ase and cleavage of caspases 3, 8, and 9 and poly(ADP ribose) polymerase, and suppressed survivin, my

126 Western blotting for the cleaved fragment of poly(ADP-ribose) polymerase, and the active isoform of c

127 y reduced cleavage of caspase-3, -8, and -9, poly(ADP-ribose) polymerase, and the externalization of

128 ntrols the activities of sirtuins, mono- and poly-(ADP-ribose) polymerases, and NAD nucleosidase.

129 hibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically ap

130 ed to modulation of Bax, Bcl2, caspase-9 and poly(ADP-ribose) polymerase as well as Reactive Oxygen S

131 caspase-8, and caspase-9 activation and less poly (ADP-ribose) polymerase cleavage compared with WT l

132 downregulation of glucose transporter-1 and poly (ADP-ribose) polymerase cleavage while preserving t

133 anism of cell death, involving apoptosis via poly (ADP-ribose) polymerase cleavage-independent of cas

134 P] followed by progressive ATP depletion and Poly ADP Ribose Polymerase cleavage, (2) increased vacuo

135 hway, which corresponded with an increase in poly ADP ribose polymerase cleavage.

136 f the DNA damage marker gammaH2AX as well as poly(ADP-ribose) polymerase cleavage were elevated in SM

137 poptosis, as assessed by caspase-3 activity, poly(ADP-ribose) polymerase cleavage, phosphatidylserine

138 hout chilling) and more than 60% cleavage of poly-ADP ribose polymerase (compared to less than 5% in

139 h the AHR target gene TiPARP (TCDD-inducible poly(ADP-ribose) polymerase) contributes to TCDD suppres

140 eath pathways demonstrated the activation of poly ADP-ribose polymerase-dependent cell death in bok-d

141 responses through its N-terminal region in a poly(ADP-ribose) polymerase-dependent manner.

142 pectively, and high selectivity toward other poly (ADP-ribose) polymerase enzymes.

143 One protein in the complex was poly ADP-ribose polymerase I (Parp1).

144 2 mutant channel (C1008-->A) or silencing of poly ADP-ribose polymerase in ECs of mice prevented PMN

145 golipids promoted cell death and cleavage of poly(ADP-ribose) polymerase in cardiomyocytes.

146 eflected by caspase-3/7 activity and cleaved poly(ADP-ribose) polymerase, in different cell lines tha

147 so enhanced ADP-ribosylation and did so by a poly(ADP-ribose) polymerase-independent mechanism.

148 a potential marker of long-term response to poly (ADP-ribose) polymerase inhibition and that restora

149 Purpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced v

150 reased sensitivity to ionizing radiation and poly (ADP-ribose) polymerase inhibition.

151 ability, hypersensitivity to DNA damage, and poly(ADP-ribose) polymerase inhibition associated with A

152 Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PA

153 rpose Durable and long-term responses to the poly (ADP-ribose) polymerase inhibitor olaparib are obse

154 Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in

155 Ialpha inhibitor, L67, in combination with a poly (ADP-ribose) polymerase inhibitor.

156 Maintenance therapy with olaparib, a poly ADP ribose polymerase inhibitor given post-platinum

157 mor-derived DNA were resistant to platin- or poly ADP ribose polymerase inhibitor-based chemotherapy.

158 rate alpha-ketoglutarate or treatment with a poly(ADP ribose) polymerase inhibitor protects reductive

159 tions initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; h

160 Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is a

161 IEL3 provides further evidence that use of a poly(ADP-ribose) polymerase inhibitor in the maintenance

162 The poly(ADP-ribose) polymerase inhibitor olaparib has shown

163 Our data, together with the advent of poly(ADP-ribose) polymerase inhibitor trials, supports t

164 Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer ac

165 Veliparib, an oral poly(ADP-ribose) polymerase inhibitor, has been shown to

166 gagement of the chemotherapeutic Olaparib, a poly(ADP-ribose) polymerase inhibitor, in live cells and

167 cells with mutant p53 were resistant to the poly(ADP-ribose) polymerase inhibitor, veliparib (2-[(2R

168 reaks (DSBs), and increased sensitivity to a poly(ADP-ribose) polymerase inhibitor.

169 y, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor.

170 Poly (ADP-ribose) polymerase inhibitors (PARPis) are cli

171 d treatments such as antiangiogenic drugs or poly (ADP-ribose) polymerase inhibitors offer potential

172 vic radiotherapy, or previous treatment with poly (ADP-ribose) polymerase inhibitors.

173 lethality anticancer therapeutics, including poly ADP-ribose polymerase inhibitors for BRCA1- and BRC

174 uely responsible for cellular sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPi) in BRCA1-

175 Although poly(ADP-ribose) polymerase inhibitors have shown promis

176 The vault-interacting domain of vault poly(ADP-ribose)-polymerase (INT) has been used as a shu

177 overexpression of caspase-3, higher cleaved poly (ADP-ribose) polymerase levels (p < 0.007), and a h

178 HR-deficient cancers are hypersensitive to Poly (ADP ribose)-polymerase (PARP) inhibitors, but can

179 We have previously demonstrated that poly (ADP-ribose) polymerase (PARP) 14, a member of the

180 emicals were tested for inhibitory effect of poly (ADP-ribose) polymerase (PARP) activity in vitro an

181 activation of caspase-8 and -3, cleavage of poly (ADP-Ribose) polymerase (PARP) and apoptosis.

182 Inhibitors against poly (ADP-ribose) polymerase (PARP) are promising target

183 ion of apoptotic cell death and detection of poly (ADP-ribose) polymerase (PARP) cleavage.

184 ore susceptible to apoptotic stress based on poly (ADP-ribose) polymerase (PARP) cleavage.

185 oded by PML-RARA) are extremely sensitive to poly (ADP-ribose) polymerase (PARP) inhibition, in part

186 Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) ol

187 recent approval of olaparib (Lynparza), the poly (ADP-ribose) polymerase (PARP) inhibitor for treati

188 tudies suggested impressive potential when a poly (ADP-ribose) polymerase (PARP) inhibitor is given f

189 izes cancer cells to DNA damaging agents, to Poly (ADP-ribose) polymerase (PARP) inhibitors and cross

190 Poly (ADP-ribose) polymerase (PARP) inhibitors have emer

191 Poly (ADP-ribose) polymerase (PARP) inhibitors have emer

192 Poly (ADP-ribose) polymerase (PARP) inhibitors have show

193 Poly (ADP-ribose) polymerase (PARP) inhibitors have show

194 Poly (ADP-ribose) polymerase (PARP) inhibitors were foun

195 ls is being targeted with platinum drugs and poly (ADP-ribose) polymerase (PARP) inhibitors.

196 y protein BIM, cleaved caspase 3 and cleaved poly (ADP-ribose) polymerase (PARP).

197 the sensitivity of BRCA1-deficient cells to poly ADP ribose polymerase (PARP) inhibition is partiall

198 /NF45-depleted HeLa cells displayed elevated poly ADP-ribose polymerase (PARP) cleavage and susceptib

199 yrases (TNKS1 and TNKS2) are proteins in the poly ADP-ribose polymerase (PARP) family.

200 ance to platinum-based chemotherapeutics and poly(ADP ribose) polymerase (PARP) inhibitors.

201 l series of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors.

202 t its chromatin accumulation was enhanced in poly(ADP-ribose) polymerase (PARP) 1(-/-) compared with

203 nM), we observed loss of CIPs and increased poly(ADP-ribose) polymerase (PARP) activation [also obse

204 We found that poly(ADP-ribose) polymerase (PARP) activation distinguis

205 (COX-2 and IL-1beta) and apoptotic markers (poly(ADP-ribose) polymerase (PARP) and caspase 3).

206 n BC3 and BCBL1 PEL cells but did not induce poly(ADP-ribose) polymerase (PARP) cleavage in virus-neg

207 hrome c release, activation of caspases, and poly(ADP-ribose) polymerase (PARP) cleavage.

208 vidence is provided that the activity of the poly(ADP-ribose) polymerase (Parp) enzyme is required fo

209 Prior work has established that the poly(ADP-ribose) polymerase (PARP) enzyme Tankyrase (TNK

210 ants into nucleosomes, and activation of the poly(ADP-ribose) polymerase (PARP) enzyme.

211 The poly(ADP-ribose) polymerase (PARP) enzymes were initiall

212 e a critical function of some members of the poly(ADP-ribose) polymerase (PARP) family in clearance o

213 The mammalian poly(ADP-ribose) polymerase (PARP) family includes ADP-r

214 rences are seen between tankyrases and other poly(ADP-ribose) polymerase (PARP) family members.

215 ld, leading the way for the discovery of the poly(ADP-ribose) polymerase (PARP) family of enzymes and

216 Tankyrases 1 and 2 are members of the poly(ADP-ribose) polymerase (PARP) family of enzymes tha

217 The poly(ADP-ribose) polymerase (PARP) family of proteins us

218 ly(ADP-ribosyl)ated and that mutation of the poly(ADP-ribose) polymerase (Parp) gene impairs their fu

219 highly toxic DNA strand breaks that trigger poly(ADP-ribose) polymerase (Parp) hyperactivation, cell

220 nfer cellular sensitization to radiation and poly(ADP-ribose) polymerase (PARP) inhibition.

221 Further, we observed that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib sy

222 ng agents melphalan and cisplatin and to the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (

223 We report results for veliparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, combined w

224 Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previo

225 nction and was recently reported as a potent poly(ADP-ribose) polymerase (PARP) inhibitor.

226 and breaks and disruption of this pathway by Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) is

227 Poly(ADP-ribose) polymerase (PARP) inhibitors can genera

228 Poly(ADP-ribose) polymerase (PARP) inhibitors have activ

229 eterogeneous responses to platinum drugs and poly(ADP-ribose) polymerase (PARP) inhibitors in clinica

230 ical trials exploiting this concept by using poly(ADP-ribose) polymerase (PARP) inhibitors in patient

231 In the present study we observed that the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib a

232 eutic drugs that block DNA repair, including poly(ADP-ribose) polymerase (PARP) inhibitors, fail due

233 tizes tumors to DNA cross-linking agents and poly(ADP-ribose) polymerase (PARP) inhibitors, we sought

234 Thus, poly(ADP-ribose) polymerase (PARP) inhibitors, which dis

235 provide insight into why clinical trials of poly(ADP-ribose) polymerase (PARP) inhibitors, which req

236 compromised DNA repair and are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors.

237 A1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors.

238 DNA-damaging agents, including cisplatin and poly(ADP-ribose) polymerase (PARP) inhibitors.

239 Poly(ADP-ribose) polymerase (PARP) is implicated in DNA

240 Activation of poly(ADP-ribose) polymerase (PARP) near sites of DNA bre

241 This study explores the role of poly(ADP-ribose) polymerase (PARP) on global gene expres

242 ication effected by enzymes belonging to the poly(ADP-ribose) polymerase (PARP) superfamily, mainly b

243 The poly(ADP-ribose) polymerase (PARP) Tankyrase (TNKS and T

244 e in colorectal cancer by interacting with a poly(ADP-ribose) polymerase (PARP) tankyrase.

245 ed caspase 3, cleaved caspase 9, and cleaved poly(ADP-ribose) polymerase (PARP), suggesting that impa

246 ed by inhibition of the NAD-consuming enzyme poly(ADP-ribose) polymerase (PARP)-1 or supplementation

247 while p65NF-kappaB phosphorylation, cleaved poly(ADP-ribose) polymerase (PARP)-1, and cyclooxygenase

248 ed caspase-3, cleaved caspase-7, and cleaved poly(ADP-ribose) polymerase (PARP).

249 of Ewing sarcoma cells to the inhibition of poly(ADP-ribose) polymerase (PARP).

250 ivo, we show that the anti-apoptotic protein poly(ADP-ribose) polymerase (PARP)14 promotes aerobic gl

251 ediated apoptosis by affecting expression of poly(ADP-ribose) polymerase (PARP)14, a key regulator of

252 Poly(ADP-ribose) polymerases (PARP) attach poly(ADP-ribo

253 r targets are the tankyrase proteins (TNKS), poly(ADP-ribose) polymerases (PARP) that regulate Wnt si

254 The enzyme poly(ADP-ribose)polymerase (PARP) has a dual function be

255 r has been the exploitation of inhibitors of poly-(ADP-ribose) polymerase (PARP) for the treatment of

256 Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis)

257 Bax and Bak, and processing of caspases and poly-(ADP-ribose) polymerase (PARP-gamma).

258 ocation from mitochondria to the nucleus and poly-(ADP-ribose)-polymerase (PARP) activation.

259 ty increases already in 1 hr after nsPEF and poly-ADP ribose polymerase (PARP) cleavage is detected i

260 Assays for DNA ladder formation and poly-ADP ribose polymerase (PARP) cleavage were performe

261 aging drugs, which is further exacerbated by poly-ADP ribose polymerase (PARP) inhibitors.

262 We show that the latonduine analogs inhibit poly-ADP ribose polymerase (PARP) isozymes 1, 3, and 16.

263 t cancer associated proteins 1, 2 (BRCA1/2), Poly-ADP ribose polymerase (PARP), replication factor c2

264 eir cellular hyper-dependence on alternative poly-ADP ribose polymerase (PARP)-mediated DNA repair me

265 ith 3dSB or 3dSB-PNBS results in cleavage of poly-ADP-ribose polymerase (PARP) and caspase-9, both ma

266 cells and is catalyzed by 11 members of the poly-ADP-ribose polymerase (PARP) family of proteins (17

267 breaks (DSBs) and were modestly sensitive to poly-ADP-ribose polymerase (PARP) inhibitors olaparib an

268 otoxic alkylating agents, hyperactivation of poly-ADP-ribose polymerase (PARP) leads to cellular NAD

269 Diabetes is known to increase poly-ADP-ribose-polymerase (PARP) activity and posttrans

270 ys conserved in all eukaryotic cells include poly (ADP-ribose) polymerases (PARPs), sirtuins, AMP-act

271 Poly ADP-ribose polymerases (PARPs) catalyze massive pro

272 The poly(ADP-ribose) polymerases (PARPs) are a major family

273 Poly(ADP-ribose) polymerases (PARPs) are involved in DNA

274 al modification, is immediately catalyzed by poly(ADP-ribose) polymerases (PARPs) at DNA lesions, whi

275 unveil the mechanisms by which inhibition of poly(ADP-ribose) polymerases (PARPs) elicits clinical be

276 longing to the tankyrase (Tnks) subfamily of poly(ADP-ribose) polymerases (PARPs) have recently been

277 Poly(ADP-ribose) polymerases (PARPs) synthesize and bind

278 posttranslational modification catalyzed by poly(ADP-ribose) polymerases (PARPs) that mediate EBV re

279 Poly(ADP-ribose) polymerases (PARPs), enzymes that modif

280 rate of tankyrases, which are members of the poly(ADP-ribose) polymerases (PARPs).

281 poly(ADP-ribose) glycohodrolases (PARGs) and poly(ADP-ribose) polymerases (PARPs).

282 sed apoptosis characterized by caspase 3 and poly(ADP-ribose) polymerase processing, DNA cleavage, an

283 of their breakage, and to be antagonized by poly (ADP-ribose) polymerase/RECQ1-regulated restart.

284 ch damages DNA and causes hyperactivation of poly(ADP-ribose) polymerase, resulting in extensive NAD(

285 otein PNKP and implicates hyperactivation of poly(ADP-ribose) polymerase/s as a cause of cerebellar a

286 RK1 inhibition cooperates with inhibition of poly (ADP-ribose) polymerase signalling to inhibit growt

287 Resolution at telomeres requires the poly(ADP-ribose) polymerase tankyrase 1, but the mechani

288 the histone variant macroH2A1.1 binds to the poly(ADP-ribose) polymerase tankyrase 1, preventing it f

289 n be induced by inhibition of tankyrase 1, a poly(ADP-ribose) polymerase that is required for resolut

290 Tankyrase 1 and 2 are poly(ADP-ribose) polymerases that function in pathways c

291 Tankyrases are poly(ADP-ribose) polymerases that have many cellular fun

292 tetrachlorodibenzo-p-dioxin (TCDD)-inducible poly(ADP-ribose) polymerase (TiPARP) gene expression, de

293 ere, we show that the loss of TCDD-inducible poly(ADP-ribose) polymerase (Tiparp), an ADP-ribosyltran

294 AhR repressor (Ahrr/AhRR) and TCDD-inducible poly(ADP-ribose)polymerase (Tiparp/TiPARP) by AhR ligand

295 se 3 and cleavage of the caspase 3 substrate poly(ADP-ribose) polymerase were inhibited in E. faecali

296 rker proteins, cleaved caspase 7 and cleaved poly(ADP-ribose) polymerase, were significantly reduced

297 Various poly(ADP-ribose) polymerases which are notorious guardia

298 This activates nuclear poly(ADP-ribose) polymerase, which inhibits GAPDH, shunt

299 ncer cells and decreases the level of intact poly(ADP-ribose) polymerase, which is indicative of apop

300 AD precursors, exercise regimens, or loss of poly(ADP-ribose) polymerases yet surprisingly do not exh